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Poster Session II 143numbers at any time point, did not correlate with any of the analysed
factors. Lower numbers of mDC and pDC in the PB at 3 months
after transplant significantly correlated with increased overall and
transplant-related mortality in univariate analysis. In multivariate
analysis low mDC counts correlated with increased overall mortal-
ity (p 5 0.008) whereas low pDC counts correlated with increased
TRM (p 5 0.07). PB Monocyte numbers instead did not correlate
with any of the analysed end points. Conclusion: Recovery of
mDC and pDC 3–12 months after transplant was reduced in pa-
tients with advanced disease at transplant, or developing acute or
chronic extensive GVHD after transplant. Nevertheless, a delayed
recovery of mDC and pDC within 3 months after transplant was
an independent factor contributing to a greater mortality.393
PRESENCE OF ACTIVATING KIR GENOTYPES INFLUENCES CYTOMEGA-
LOVIRUS (CMV) REACTIVATION AS DETECTED BY Q-PCR IN HCT RECIP-
IENTS
Sun, J.1, Gallez-Hawkins, G.M.2, Thao, L.2, Li, X.2, Franck, A.E.2,
Dagis, A.3, Senitzer, D.1, Forman, S.J.1, Zaia, J.A.2. 1City of Hope,
Duarte, CA; 2Beckman Research Institute of City of Hope, Duarte,
CA; 3City of Hope, Duarte, CA.
Killer Ig-like receptor (KIR) is a cluster of natural killer cell re-
ceptors presented by T cells and natural killer (NK) cells. The com-
patibility of these receptors between the donor and the recipient
plays a role in hematopoietic cell transplantation (HCT) for either
activating (aKIR) or inhibitory KIRs. Some aKIRs bind only weakly
to HLA class I and the natural ligands remain undetermined
whereas the inhibitory KIRs bind HLA class I molecules with spec-
ificity for defined alleles of HLA-C, HLA-B, or HLA-A. It has been
suggested that the donor KIR genotype influences the rate of CMV
infection and, more particularly, that aKIR genes are inversely asso-
ciated with CMV reactivation (Cook et al Blood 2006; 107: 1230–
32; Chen et al. BMT 2006; 38: 437–44). In this study, a cohort of
92 non T-cell depleted subjects, who had received a matched unre-
lated or HLA identical related donor, were analyzed for inhibitory
KIR ligands and KIR genotypes obtained using a multiplex PCR-
SSPmethod. All recipients were at risk for CMV reactivation which
was monitored bi-weekly by Q-PCR on plasma DNA.
Results: Two groups, those with CMV reactivation (n 5 68) vs
No CMV (n 5 24), were compared for the presence of KIR deter-
minants and analyzed using a contingency table with Chi2 test for
probability values. An increased number of aKIR genes in the do-
nor, either involving an A haplotype, carrying a single aKIR gene,
or the AB and BB haplotypes carrying more than one aKIRs, was
significantly associated with a reduction of CMV reactivation (p
5 0.0438). In addition, using a previously described algorithm for
scoring KIR determinants in donor and recipient (Sun et al. BMT
2005; 56: 525–530), values .0, associated with more aKIRs in the
donor but not in the recipient, were associated with significantly
less CMV reactivation (62%VS 85%, p5 0.0372).When the recip-
ients were analyzed for HLA-CwKIR ligand group1 or 2, there was
no significant association with CMV reactivation. This was still true
whenHLA class I mismatched donor-recipient pairs were excluded.
Conclusion: In theHCT setting, aKIR genes in donor cells protect
the recipient from CMV reactivation but the HLA-Cw allotype of
the recipient does not predict CMV infection.394
VACCINATION WITH CARNARYPOX PP65 CMV VACCINE INDUCES RELI-
ABLE CD41 AND CD81 T CELL RESPONSES ONLY IN INDIVIDUALS
WHO LACK BASELINE RESPONSES. IMPLICATIONS FOR DONOR VACCI-
NATION TO BOOST CMV IMMUNITY IN STEM CELL TRANSPLANT RECIP-
IENTS
Shenoy, A.1, Solomon, S.2, Pichon, S.3, Cadoz, M.3, Barrett, A.J.1.
1NIH, Bethesda, MD; 2The Blood and Marrow Transplant Program,
Atlanta, GA; 3Sanofi Pasteur, Marcy L’etoile, France.CMV reactivation after allogeniec stem cell transplant (SCT) re-
mains a major cause of post-transplant morbidity but may be miti-
gated by strong T-cell responses in the transplanted donor T-cell
repertoire.We vaccinated 25 subjects with ‘‘ALVAC pp-65’’ (sanofi
pasteur, Lyon, France) to boost CMV responses in seropositive sub-
jects and induce CMV responses in seronegative subjects. An accel-
erated regimen giving 1.0 ml ALVAC pp-65 on days 0 and 5 to
seropositive subjects and days 0, 5, and 10 to seronegative individ-
uals was used. CD41 and CD81 T-cell responses to a CMV
pp65 peptide library were measured at serial timepoints post vacci-
nation using flow cytometry to identify interferon-gamma produc-
ing T-cells. Positive responses were defined as a twofold increase of
interferon-gamma production compared to unstimulated cells. Of
the 25 subjects analyzed, 13 were seropositive and 12 were seroneg-
ative. As previously reported, serostatus did not correlate with base-
line CD41 and CD81 CMV response. Indeed there were no
differences in T-cell response patterns according to serostatus.
We therefore segregated subjects into baseline CD41 or CD81 re-
sponders or non-responders irrespective of serostatus. Six of 9
CD41 non-responders had a 2–8 fold (median 4) increase in re-
sponse by day 5. In contrast, 13 of 16 subjects with a baseline
CD4 response (identified by a stimulation index of $2 at baseline)
showed decreased or undetectable responses at day 5 with variable
responses thereafter. Nine of 11 CD81 non-responders had a 2–9
fold (median 3) response by day 5. In contrast, 10 of 14 CD81 re-
sponders showed decreased response by day 5 with variable re-
sponses thereafter. Apart from pain at the injection site, vaccine
was well tolerated. These results show that ALVAC is a well toler-
ated vaccine with the potential to induce pp65 responses in subjects
who lack baseline responses. In subjects that have baseline re-
sponses, vaccination appears to dampen immediate immune re-
sponse. It is unclear if the vaccine is inducing tolerance in these
individuals and if this is related to dose of the vaccine. ALVAC
pp65 can elicit quick responses of varying duration in subjects
that lack CD4 or CD81T cell responses to CMV and could there-
fore be used to improve the transfer of CMV immunity to SCT re-
cipients using such donors. However, in donors that have a baseline
CMV response, vaccination may be detrimental to the recipients’
ability to respond to CMV.395
IMPACT OF DONOR T CELLS ON B CELL DEVELOPMENT AFTER HEMA-
TOPOIETIC CELL TRANSPLANTATION: LESSONS FROM B CELL DEFI-
CIENT MICE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Tung, J.W.3,
Shizuru, J.A.1. 1Stanford School of Medicine, Stanford, CA; 2University
Medical Center, Freiburg i.Br., Germany; 3Stanford School of Medicine,
Stanford, CA.
Allogeneic hematopoietic cell transplant (HCT) recipients often
exhibit B cell (BC) lymphopenia due, in part, to graft-versus-host-
disease (GVHD). Here, we studied the influence of donor T cells
(TC) on BC deficiency post-HCT. Following lethal irradiation,
BALB. B mice were given FACS purified hematopoietic stem cells
(HSC: cKIT1Thy1.1loLin-Sca-11) alone, or with co-transfer of
whole splenocytes (SP), CD4 or CD8 TCs from minor antigen-
mismatched C57BL/6 (B6) mice. When pure HSC were trans-
planted, BC reconstituted promptly (median 33% of lymphocytes
[d30]; 61% [d60]; 74% [d90]), whereas TC engraftment was re-
tarded and did not achieve full donor chimerism. In contrast, addi-
tion of SP or CD4 TCs substantially suppressed BC reconstitution,
correlating with the degree of acute GVHD, and TC transfer ad-
vanced TC engraftment and resulted in early conversion to full do-
nor chimerism. To test if previous events in the donor sensitize TCs
against BC structures, thereby promoting anti-BC cytotoxicity
post-HCT, TCs from B cell deficient mMTB6 mice were co-trans-
planted with wild type (WT) HSC. Remarkably, BC engraftment
was completely prevented through d90. TCs regenerated faster,
but the vast majority originated from spleen and not HSC. To dif-
ferentiate this lack of BC engraftment from GVHD-associated al-
loreactive BC lymphopenia, syngenic B6 recipients were used.
Again, initially complete blockade of BC engraftment was observed,
although this suppression was overcome earlier post-HCT as
